STVN STEVANATO GRP SPA

Stevanato Group to Report Third Quarter 2024 Financial Results on November 5, 2024

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET).

Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website.

Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants are encouraged to pre-register for the conference call using the following link: .

Webcast: A live, listen-only webcast of the call will be available at the following link:

Dial in: Those who are unable to pre-register may dial in by calling:

Italy:

1

United Kingdom:

4

United States:

United States Toll Free:

Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link:

Replay:

The webcast will be archived for three months on the Investor Relations section of the Company’s website.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions, as well as engineering solutions to the pharmaceutical, biotechnology and life sciences industries. Stevanato Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug lifecycle from development to clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value-added solutions to clients. For more information, please visit .

EN
22/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on STEVANATO GRP SPA

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Stevanato Group to Present at Upcoming Investor Conferences

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming investor conferences. The Company will participate in a fireside chat at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, November 12, 2024 at 11:00 a.m. (PT). The Company will also present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 9:00 a.m. (GMT), and ...

 PRESS RELEASE

Stevanato Group Reports Financial Results for the Third Quarter of 202...

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with the same period last year, and high-value solutions represented 36% of total revenue. For the third quarter, diluted earnings per share were €0.11 and adjusted diluted earnings per...

 PRESS RELEASE

Stevanato Group to Report Third Quarter 2024 Financial Results on Nove...

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be a...

 PRESS RELEASE

Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic In...

PIOMBINO DESE, Italy--(BUSINESS WIRE)-- (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together with (MDAX: GXI) and (MDAX: 1SXP), announced today that they have entered into a strategic industry alliance ("Alliance for RTU") to support market adoption of Ready-to-Use (RTU) vials and cartridges. This press release features multimedia. View the full release here: Stevanato Group, Gerresheimer & SCHOTT Pharma join forces in the 'Alliance for RTU' (Photo: Business Wire) The A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch